胰激肽原酶肠溶片联合鼠神经生长因子制剂治疗糖尿病痛性神经病变的临床观察

The Therapeutic Effect of Combinative Application of Mouse Nerve Growth Factor and Pancreatic Kininogenase Enteric-Coated Tablets On Diabetic Peripheral Neuropathy

目的观察胰激肽原酶肠溶片联合鼠神经生长因子治疗痛性神经病变的临床观察。方法 2型糖尿病105例分为两组,治疗组53例,采用胰激肽原酶肠溶片联合鼠神经生长因子治疗,对照组52例采用鼠神经生长因子治疗,疗程均为21 d,治疗前后两组均检查血糖、血脂及血流变,治疗组检查双下肢血管多普勒,结果治疗组总有效率,对照组总有效率,两组疗效比较有统计学差异(P<0.05),未见明显不良反应。结论胰激肽原酶肠溶片联合鼠神经生长因子治疗痛性神经病变的疗效优于单用胰激肽原酶肠溶片的治疗效果。

Objective To evaluate of the effect of combinative application of mouse nerve growth factor and pancreatic kininogenase enteric-coated tables on diabetic peripheral neuropathy（DPN）. Methods 105 patients with diabetes were devided into two groups randomly. 53 pations with diabetes were given buflomedil and pancreatic kininogenase enteric-coated tables（observation group） and another 52 patients were give mouse nerve growth factor（control group） for 21 days. Results The total efficiency rate was 94.33% in the observation group, while it was 53.85% in the control group（P〈0.05）. The improvement in symptoms was more obvious in observation group. Conclusions The effectiveness of combinative application of mouse nerve growth factor and pancreatic kininogenase enteric-coated tablets for DPN is better than single use of mouse nerve growth factor.